These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 28625207)

  • 1. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
    Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM
    Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.
    Rosenberg PB; Mielke MM; Han D; Leoutsakos JS; Lyketsos CG; Rabins PV; Zandi PP; Breitner JC; Norton MC; Welsh-Bohmer KA; Zuckerman IH; Rattinger GB; Green RC; Corcoran C; Tschanz JT
    Int J Geriatr Psychiatry; 2012 Dec; 27(12):1248-57. PubMed ID: 22374884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
    Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
    J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland.
    Moga DC; Taipale H; Tolppanen AM; Tanskanen A; Tiihonen J; Hartikainen S; Wu Q; Jicha GA; Gnjidic D
    Drugs Aging; 2017 Jan; 34(1):55-65. PubMed ID: 27896799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study.
    Hongisto K; Hallikainen I; Selander T; Törmälehto S; Väätäinen S; Martikainen J; Välimäki T; Hartikainen S; Suhonen J; Koivisto AM
    Int J Geriatr Psychiatry; 2018 Jan; 33(1):47-57. PubMed ID: 28067961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer's Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM).
    Pirker-Kees A; Dal-Bianco P; Schmidt R
    J Alzheimers Dis; 2019; 71(2):623-630. PubMed ID: 31424389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study.
    Hallikainen I; Hongisto K; Välimäki T; Hänninen T; Martikainen J; Koivisto AM
    J Alzheimers Dis; 2018; 61(4):1367-1376. PubMed ID: 29376861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between Cognition and Activities of Daily Living in Alzheimer's Disease During a 5-Year Follow-Up: ALSOVA Study.
    Saari T; Hallikainen I; Hänninen T; Räty H; Koivisto A
    J Alzheimers Dis; 2018; 64(1):269-279. PubMed ID: 29889073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Positive Effects of Pet Ownership on Alzheimer's Disease.
    Rusanen M; Selander T; Kärkkäinen V; Koivisto A
    J Alzheimers Dis; 2021; 84(4):1669-1675. PubMed ID: 34719492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment.
    M FM; Molano A; Castro J; Zarranz JJ
    Curr Alzheimer Res; 2010 Sep; 7(6):517-26. PubMed ID: 20455862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric Symptoms in Alzheimer's Disease Are the Main Determinants of Functional Impairment in Advanced Everyday Activities.
    Delgado C; Vergara RC; Martínez M; Musa G; Henríquez F; Slachevsky A
    J Alzheimers Dis; 2019; 67(1):381-392. PubMed ID: 30584142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease.
    Orsel K; Taipale H; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Gardarsdottir H; Hartikainen S
    Eur Neuropsychopharmacol; 2018 Nov; 28(11):1260-1269. PubMed ID: 30153953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug use in persons with and without Alzheimer's disease aged 90 years or more.
    Taipale H; Koponen M; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
    Age Ageing; 2016 Nov; 45(6):900-904. PubMed ID: 27609205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort.
    Taipale H; Koponen M; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1729-37. PubMed ID: 25453487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of medications on physical function and cognition in nursing home residents with dementia.
    Dutcher SK; Rattinger GB; Langenberg P; Chhabra PT; Liu X; Rosenberg PB; Leoutsakos JM; Simoni-Wastila L; Walker LD; Franey CS; Zuckerman IH
    J Am Geriatr Soc; 2014 Jun; 62(6):1046-55. PubMed ID: 24823451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study.
    Bellelli G; Lucchi E; Minicuci N; Rozzini L; Bianchetti A; Padovani A; Trabucchi M
    Aging Clin Exp Res; 2005 Feb; 17(1):54-61. PubMed ID: 15847123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.